,
Jäntti, Toni https://orcid.org/0000-0001-8348-0844
Tarvasmäki, Tuukka
Harjola, Veli-Pekka
Pulkki, Kari
Turkia, Heidi
Sabell, Tuija
Tolppanen, Heli
Jurkko, Raija
Hongisto, Mari
Kataja, Anu
Sionis, Alessandro
Silva-Cardoso, Jose
Banaszewski, Marek
DiSomma, Salvatore
Mebazaa, Alexandre
Haapio, Mikko
Lassus, Johan
Funding for this research was provided by:
Aarne Koskelon Säätiö (.)
Sydäntutkimussäätiö (-)
Article History
Received: 31 August 2020
Accepted: 20 January 2021
First Online: 5 February 2021
Ethics approval and consent to participate
: The study was approved by all local ethics committees and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient or next of kin if the patients were unable to give the consent on admission.
: Not applicable.
: VPH: advisory board fees from Roche Diagnostics, research grant from Abbott, speaker fees from Orion. KP: advisory board fees from Roche Diagnostics. JSC has consulted and received speaker fees, or advisory boards’ participation fees, or investigational grants for Abbott, Astra-Zeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servier and Vifor. AM: lecture fees from Novartis, Orion, and Abbott, research grants from Roche, consultant fees from Servier and Sanofi and fees as a member of the advisory board and/or steering committee from Cardiorentis, Adrenomed, Sphingotec, Sanofi, Roche, Abbott, and Bristol-Myers Squibb. JL: Speakers bureau and consultancy fees: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, and ViforPharma. All other authors report that they have no relationships with industry to disclose.